Register using the link, available below!

Join expert pathologist, Magali Lacroix-Triki, and Owkin senior data scientist, Valentin Guary, as they present new findings on RlapsRisk® BC, an innovative AI-driven solution for breast cancer recurrence risk assessment from digital pathology slides. This webinar will showcase comprehensive data comparing RlapsRisk® BC’s performance against traditional clinical scores and established molecular tests. Our panel will discuss how this revolutionary tool helps to enhance prognostic accuracy and has the potential to transform treatment decision-making in breast cancer care.

Attendees will gain valuable insights into:
▪ The impact of AI-powered digital pathology solutions for outcome and prognostic prediction
▪ Latest performance results from ongoing studies
▪ First comparisons with current testing approaches
▪ Real-world implementation experiences
▪ Potential impact on treatment planning and patient care

RlapsRisk® BC is under development and not for clinical use. It is not FDA cleared or approved in the USA. RlapsRisk® BC is developed within the PortrAIt consortium, a french consortium financed by the government within the framework of France 2030 and by the European Union – Next Generation EU within the framework of the France Relance Plan.